Abstract:Background Allergic rhinitis (AR) is one of the most widespread immune conditions worldwide. However, common treatments often present with significant side effects or are cost-prohibitive for much of the population. A plethora of treatments have been used for the treatment of AR including antihistamines, steroids, and immune modulators. Among the treatments which have shown potential for efficacy in treating AR with a minimum of side effects but remains understudied is the conditionally essential amino acid taurine. Taurine has been previously shown to reduce AR symptoms. Here, we examine the role of taurine in modulating T regulatory cells, modulating the cytokine response in AR, and restoring healthy nasal mucosa. Methods Blood samples from 20 healthy donors and 20 AR patients were compared for CD4(+)CD25(+)FoxP3(+) T regulatory (Treg) cell population percentage, cytokine release, and STAT1 signaling with and without taurine treatment or IL-35 neutralization. An OVA-induced AR mouse model was administered vehicle, taurine, or taurine plus an IL-35 neutralizing antibody and assayed for sneezing frequency, inflammatory cytokine response, nasal mucosa goblet cell density, and T regulatory cell percentage. CD4(+) cells were further examined for cytokine release, STAT1 phosphorylation, and response to an anti-IL-35 antibody with and without a STAT1 inhibitor. Results Comparison of blood from normal donors and AR patients showed a reduction in CD4(+)CD25(+)FoxP3(+) Treg cells in AR patients and a strong correlation between Treg percentage and IL-35 release. A similar pattern of Treg suppression was found in untreated AR mice when compared to normal control mice wherein there was a reduction in Treg percentage and a corresponding decrease in IL-35 release. AR mice also demonstrated increased sneezing frequency, an infiltration of goblet cell in nasal mucosa, and a reduction in IL-35 release from CD4(+) cells. Conversely, IL-4, IL-5, and IL-13 secretion from CD4(+) cells were increased in AR model mice, as was STAT1 phosphorylation. When AR mice were treated with taurine, sneezing frequency and nasal mucosa goblet cell content were reduced while Treg abundance was increased to that of normal mice. Accordingly, IL-35 release was restored, while IL-4, IL-5, and IL-13 secretion from CD4(+) cells were suppressed. Likewise, STAT1 phosphorylation was inhibited with taurine treatment. Taurine-treated mice also given an IL-35 neutralizing antibody exhibited AR pathology including frequent sneezing and high nasal goblet cell content while retaining a restoration of Tregs. Furthermore, murine AR model CD4(+) cells exposed to recombinant IL-35 responded with a reduction in inflammatory cytokine release and a decrease in STAT1 phosphorylation, mimicking the effect of taurine treatment. Conclusions Taurine induces release of IL-35 in AR; IL-35 promotes the production of CD4(+)CD25(+)FoxP3(+) Treg cells via a STAT1-dependent pathway. The restoration of Treg populations by taurine normalizes the inflammatory response, reduces AR symptomology, and reduces histopathologic signs of AR.

Tangeretin Promotes Regulatory T Cell Differentiation by Inhibiting Notch1/Jagged1 Signaling in Allergic Rhinitis.

Assessment of Tumor Growth Factor-Β1 Neutralizing Antibody in the Treatment of Allergic Rhinitis and Asthma.

Effect of Tong Qiao drops on the expression of eotaxin, IL-13 in the nasal mucosa of rats with allergic rhinitis.

Notch Signaling Promotes Development of Allergic Rhinitis by Suppressing Foxp3 Expression and Treg Cell Differentiation.

Notch2-dependent GATA3+Treg cells alleviate allergic rhinitis by suppressing the Th2 cell response

Taurine Promotes the Production of CD4+CD25+FOXP3+ Treg Cells Through Regulating IL-35/STAT1 Pathway in a Mouse Allergic Rhinitis Model

Notch2 Suppresses the Development of Allergic Rhinitis by Promoting FOXP3 Expression and Treg Cell Differentiation

Derp1-modified dendritic cells attenuate allergic inflammation by regulating the development of T helper type1(Th1)/Th2 cells and regulatory T cells in a murine model of allergic rhinitis

Apigenin attenuates inflammatory response in allergic rhinitis mice by inhibiting the TLR4/MyD88/NF-κB signaling pathway

Prostaglandin E2 inhibits the differentiation of T regulatory cells by Peroxisome Proliferator-Activated Receptor-Gamma during allergic rhinitis

Changes in Percentage of GATA3+regulatory T Cells and Their Pathogenic Roles in Allergic Rhinitis

Adoptive Cell Therapy of Tolerogenic Dendritic Cells As Inducer of Regulatory T Cells in Allergic Rhinitis

Maggot Extracts Promote Regulatory T Cell Differentiation by Upregulating Foxp3 in Allergic Rhinitis.

Tangeretin Inhibits IL-12 Expression and NF-κB Activation in Dendritic Cells and Attenuates Colitis in Mice

Immunoregulatory role of tolerogenic dendritic cells in allergic rhinitis in mice

Tnf-Tnfr2 Signaling Inhibits Th2 And Th17 Polarization And Alleviates Allergic Airway Inflammation

An aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress the Th17 response in allergic rhinitis patients

Allergen Immunotherapy Enhances the Immunosuppressive Effects of Treg Cells to Alleviate Allergic Rhinitis by Decreasing PU-1+ Treg Cell Numbers.

MicroRNA-345-5p acts as an anti-inflammatory regulator in experimental allergic rhinitis via the TLR4/NF-κB pathway

In Vitro and in Vivo Antiallergic Effects of Taurine on Allergic Rhinitis

Inhibition of TRPA1 Reduces Airway Inflammation and Hyperresponsiveness in Mice with Allergic Rhinitis.